Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 4Phase 4 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 4

Sponsor Class

NIH 6INDUSTRY 4OTHER 3

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Diphenhydramine × Clear all
NCT03324113 2025-08-05

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

Sanofi

Phase 1 Completed
34 enrolled
Tumor-Agnostic

Neoplasms

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
240 enrolled 1 FDA
Plasma cell

Multiple Myeloma

NCT04580121 2024-06-03

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Hoffmann-La Roche

Phase 1 Completed
59 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02648490 2019-07-30

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Henlix, Inc

Phase 1 Completed
19 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡